William Jacob Savage Gemini Therapeutics, Inc. (GMTX) insider trading activity

William Jacob Savage is Chief Medical Officer of Gemini Therapeutics, Inc. . Currently has a direct ownership of 78,845 shares of GMTX, which is worth approximately $1.92 Million. The most recent transaction as insider was on Dec 22, 2025, when has been sold 3,143 shares (Common Stock) at a price of $11.07 per share, resulting in proceeds of $34,793. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 78.8K

11.21% 3M change

95.14% 12M change

Total Value Held $1.92 Million

William Jacob Savage Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 22 2025	BUY Exercise of conversion of derivative security	$34,793 $11.07 p/Share	3,143 Added 3.83%	78,845 Common Stock
Dec 15 2025	SELL Open market or private sale	$1,196,962 $91.42 p/Share	13,093 Reduced 14.75%	75,702 Common Stock
Jun 27 2025	BUY Exercise of conversion of derivative security	$316,210 $9.86 p/Share	32,070 Added 26.53%	88,795 Common Stock
Jun 06 2025	SELL Open market or private sale	$149,800 $50.0 p/Share	2,996 Reduced 5.02%	56,725 Common Stock
May 20 2025	SELL Open market or private sale	$334,117 $50.04 p/Share	6,677 Reduced 10.06%	59,721 Common Stock
May 02 2025	SELL Open market or private sale	$105,357 $50.17 p/Share	2,100 Reduced 3.07%	66,398 Common Stock
Feb 18 2025	SELL Open market or private sale	$89,402 $54.58 p/Share	1,638 Reduced 2.34%	68,498 Common Stock

Feb 10 2025	BUY Grant, award, or other acquisition	-	24,000 Added 25.5%	70,136 Common Stock
Feb 03 2025	BUY Exercise of conversion of derivative security	$15,187 $2.65 p/Share	5,731 Added 11.05%	46,136 Common Stock
Nov 25 2024	SELL Open market or private sale	$935,085 $65.93 p/Share	14,183 Reduced 25.98%	40,405 Common Stock
Nov 25 2024	BUY Exercise of conversion of derivative security	$165,657 $11.68 p/Share	14,183 Added 20.62%	54,588 Common Stock
Nov 15 2024	SELL Open market or private sale	$551,952 $60.27 p/Share	9,158 Reduced 18.48%	40,405 Common Stock
Nov 15 2024	BUY Exercise of conversion of derivative security	$90,297 $9.86 p/Share	9,158 Added 15.6%	49,563 Common Stock
Sep 16 2024	SELL Open market or private sale	$71,115 $47.41 p/Share	1,500 Reduced 3.58%	40,405 Common Stock
Sep 03 2024	SELL Open market or private sale	$75,885 $50.59 p/Share	1,500 Reduced 3.46%	41,905 Common Stock
Apr 10 2024	BUY Exercise of conversion of derivative security	$57,955 $2.65 p/Share	21,870 Added 33.5%	43,405 Common Stock
Jan 10 2024	BUY Grant, award, or other acquisition	-	18,535 Added 46.26%	21,535 Common Stock
Aug 21 2023	BUY Exercise of conversion of derivative security	$7,950 $2.65 p/Share	3,000 Added 50.0%	3,000 Common Stock
Aug 15 2023	SELL Open market or private sale	$407,843 $53.16 p/Share	7,672 Reduced 100.0%	0 Common Stock
Aug 09 2023	SELL Open market or private sale	$413,532 $50.01 p/Share	8,269 Reduced 51.87%	7,672 Common Stock
Jun 28 2023	SELL Open market or private sale	$219,068 $49.97 p/Share	4,384 Reduced 21.57%	15,941 Common Stock

WJS

William Jacob Savage

Chief Medical Officer

Watertown, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells GMTX shares.

Notify only if

Value

Insider Trading

Get notified when an Gemini Therapeutics, Inc. insider buys or sells GMTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Gemini Therapeutics, Inc.

Track Activities on GMTX

Account